136 related articles for article (PubMed ID: 35079389)
1. Acute worsening of glycemic control in a patient with type 2 diabetes and non-small cell lung cancer after administration of lorlatinib.
Nakano Y; Miyasato-Isoda M; Gohma I; Fujisawa T
Clin Case Rep; 2022 Jan; 10(1):e05283. PubMed ID: 35079389
[TBL] [Abstract][Full Text] [Related]
2. Transformation of NSCLC to SCLC harboring EML4-ALK fusion with V1180L mutation after alectinib resistance and response to lorlatinib: A case report and literature review.
Lingling X; Maoxi C; Wei Y; Jieting Z; Yuanyuan Y; Ning X
Lung Cancer; 2023 Dec; 186():107415. PubMed ID: 37907052
[TBL] [Abstract][Full Text] [Related]
3. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.
Shaw AT; Felip E; Bauer TM; Besse B; Navarro A; Postel-Vinay S; Gainor JF; Johnson M; Dietrich J; James LP; Clancy JS; Chen J; Martini JF; Abbattista A; Solomon BJ
Lancet Oncol; 2017 Dec; 18(12):1590-1599. PubMed ID: 29074098
[TBL] [Abstract][Full Text] [Related]
4. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
Solomon BJ; Besse B; Bauer TM; Felip E; Soo RA; Camidge DR; Chiari R; Bearz A; Lin CC; Gadgeel SM; Riely GJ; Tan EH; Seto T; James LP; Clancy JS; Abbattista A; Martini JF; Chen J; Peltz G; Thurm H; Ou SI; Shaw AT
Lancet Oncol; 2018 Dec; 19(12):1654-1667. PubMed ID: 30413378
[TBL] [Abstract][Full Text] [Related]
5. Lorlatinib for advanced anaplastic lymphoma kinase-positive non-small cell lung cancer: Results of the IFCT-1803 LORLATU cohort.
Baldacci S; Besse B; Avrillon V; Mennecier B; Mazieres J; Dubray-Longeras P; Cortot AB; Descourt R; Doubre H; Quantin X; Duruisseaux M; Monnet I; Moro-Sibilot D; Cadranel J; Clément-Duchêne C; Cousin S; Ricordel C; Merle P; Otto J; Schneider S; Langlais A; Morin F; Westeel V; Girard N
Eur J Cancer; 2022 May; 166():51-59. PubMed ID: 35278825
[TBL] [Abstract][Full Text] [Related]
6. Enteral lorlatinib after immune hyperprogression as a treatment option for anaplastic lymphoma kinase‑positive non‑small cell lung cancer: A case report.
Wang H; Wu Z; Shi G; Zhou J; Xiao Z
Oncol Lett; 2023 Dec; 26(6):526. PubMed ID: 38020308
[TBL] [Abstract][Full Text] [Related]
7. Safety of lorlatinib following alectinib-induced pneumonitis in two patients with
Myall NJ; Lei AQ; Wakelee HA
Transl Lung Cancer Res; 2021 Jan; 10(1):487-495. PubMed ID: 33569330
[TBL] [Abstract][Full Text] [Related]
8. Successful treatment with lorlatinib in a patient with meningeal carcinomatosis of ALK-positive non-small cell lung cancer resistant to alectinib and brigatinib: A case report.
Nakashima K; Demura Y; Kurokawa K; Takeda T; Jikuya N; Oi M; Tada T; Akai M; Ishizuka T
Medicine (Baltimore); 2021 Oct; 100(39):e27385. PubMed ID: 34596160
[TBL] [Abstract][Full Text] [Related]
9. Lorlatinib for the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer.
Yang J; Gong W
Expert Rev Clin Pharmacol; 2019 Mar; 12(3):173-178. PubMed ID: 30657349
[TBL] [Abstract][Full Text] [Related]
10. Safety of lorlatinib in ALK-positive non-small-cell lung cancer and management of central nervous system adverse events.
Kilickap S; Ak S; Dursun OU; Sendur MA; Karadurmus N; Demirci U
Future Oncol; 2023 Sep; 19(29):2003-2012. PubMed ID: 37449387
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of first-line treatments for patients with advanced anaplastic lymphoma kinase mutated, non-small cell cancer: A systematic review and network meta-analysis.
Peng Y; Zhao Q; Liao Z; Ma Y; Ma D
Cancer; 2023 Apr; 129(8):1261-1275. PubMed ID: 36748799
[TBL] [Abstract][Full Text] [Related]
12. Lorlatinib for advanced ROS1+ non-small-cell lung cancer: results of the IFCT-1803 LORLATU study.
Girard N; Galland-Girodet S; Avrillon V; Besse B; Duruisseaux M; Cadranel J; Otto J; Prevost A; Roch B; Bennouna J; Bouledrak K; Coudurier M; Egenod T; Lamy R; Ricordel C; Moro-Sibilot D; Odier L; Tillon-Strozyk J; Zalcman G; Missy P; Westeel V; Baldacci S
ESMO Open; 2022 Apr; 7(2):100418. PubMed ID: 35227966
[TBL] [Abstract][Full Text] [Related]
13. A novel ROS1 G2032 K missense mutation mediates lorlatinib resistance in a patient with ROS1-rearranged lung adenocarcinoma but responds to nab-paclitaxel plus pembrolizumab.
Zhou Y; Jiang W; Zeng L; Mi J; Song L; Lizaso A; Mao X; Yang N; Zhang Y
Lung Cancer; 2020 May; 143():55-59. PubMed ID: 32208297
[TBL] [Abstract][Full Text] [Related]
14. Yes-associated protein 1 mediates initial cell survival during lorlatinib treatment through AKT signaling in ROS1-rearranged lung cancer.
Yamazoe M; Ozasa H; Tsuji T; Funazo T; Yoshida H; Hashimoto K; Hosoya K; Ogimoto T; Ajimizu H; Yoshida H; Itotani R; Sakamori Y; Kuninaga K; Aoki W; Hirai T
Cancer Sci; 2023 Feb; 114(2):546-560. PubMed ID: 36285485
[TBL] [Abstract][Full Text] [Related]
15. Patient-reported outcomes from the randomized phase 3 CROWN study of first-line lorlatinib versus crizotinib in advanced ALK-positive non-small cell lung cancer.
Mazieres J; Iadeluca L; Shaw AT; Solomon BJ; Bauer TM; de Marinis F; Felip E; Goto Y; Kim DW; Mok T; Reisman A; Thurm H; Polli AM; Liu G
Lung Cancer; 2022 Dec; 174():146-156. PubMed ID: 36410210
[TBL] [Abstract][Full Text] [Related]
16. Cost-Effectiveness of Lorlatinib for the Treatment of Adult Patients with Anaplastic Lymphoma Kinase Positive Advanced Non-Small Cell Lung Cancer in Spain.
Presa M; Vicente D; Calles A; Salinas-Ortega L; Naik J; García LF; Soto J
Clinicoecon Outcomes Res; 2023; 15():659-671. PubMed ID: 37701861
[TBL] [Abstract][Full Text] [Related]
17. Combined Lorlatinib, Dabrafenib, and Trametinib Treatment for
Li D; Liu J; Zhang X; Han J; Jin H; Wang L; Feng L; Fan Z; Zuo J; Wang Y
Cancer Manag Res; 2022; 14():3175-3179. PubMed ID: 36411743
[TBL] [Abstract][Full Text] [Related]
18. Real-world therapeutic effectiveness of lorlatinib after alectinib in Japanese patients with ALK-positive non-small-cell lung cancer.
Goto Y; Shukuya T; Murata A; Kikkawa H; Emir B; Wiltshire R; Miura S
Cancer Sci; 2023 Jun; 114(6):2560-2568. PubMed ID: 36866958
[TBL] [Abstract][Full Text] [Related]
19. Enteral lorlatinib after alectinib as a treatment option in anaplastic lymphoma kinase-positive non-small cell lung cancer with triple problems: carcinomatous meningitis, poor performance status, and dysphagia-a case report.
Sasaki K; Yokota Y; Isojima T; Fujii M; Hasui K; Chen Y; Saito K; Takahata T; Kindaichi S; Sato A
Respirol Case Rep; 2021 Jul; 9(7):e00796. PubMed ID: 34123384
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of lorlatinib in Asian and non-Asian patients with ALK-positive advanced non-small cell lung cancer: Subgroup analysis of a global phase 2 trial.
Soo RA; Huat Tan E; Hayashi H; Seto T; Lin CC; Ou SI; Kim DW; Liu G; Abbattista A; Martini JF; Hooi Wong C; Toffalorio F; Solomon BJ
Lung Cancer; 2022 Jul; 169():67-76. PubMed ID: 35660971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
